AstraZeneca PLC is 201.6x more valuable than ArriVent BioPharma, Inc. by market capitalization ($286.27 B vs $1.42 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AVBP | AZN |
|---|---|---|
| Market cap | $1.42 B | $286.27 B |
| US-listed rank | #2366 | #45 |
| Net income (latest FY) | -$166.31M | - |
| SEC filings | 144 | 1,004 |
AstraZeneca PLC is 201.6x more valuable than ArriVent BioPharma, Inc. by market capitalization ($286.27 B vs $1.42 B).
Full pages: ArriVent BioPharma, Inc. and AstraZeneca PLC, or browse the full rankings.